EQS-Adhoc: Ad-hoc: Marinomed Biotech AG plans to apply for court restructuring proceedings without self-administration
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Insolvency Korneuburg, Austria, 16th July 2026 – Marinomed Biotech AG (VSE:MARI) announces the plan to apply for the initiation of a court restructuring proceeding without self-administration. The application is being filed because the court-approved restructuring plan dated November 14, 2024, cannot be fulfilled due to the breakdown of negotiations by Unither and the failure of Unither Pharmaceuticals to make earn-out payments from the sale of the Carragelose business unit, thereby placing the company at risk of insolvency. The aim of the renewed restructuring proceedings without self-administration is to secure the company's financial stability by concluding a new restructuring plan. In addition to further restructuring measures, the legal options available against Unither arising from the sale of the Carragelose business and the assets of the Marinosolv platform are to be utilized.
+++ End of ad-hoc announcement +++ End of Inside Information
16-Jul-2026 CET/CEST News transmitted by EQS Group |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official Market) |
| LEI Code: | 529900GN3B1EN80XF405 |
| EQS News ID: | 2367244 |
| End of Announcement | EQS News Service |
|
|
2367244 16-Jul-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 8,12 | 11,63 | 11,28 | 9,18 | 4,75 | 7,69 | 0,00 | |
| EBITDA1,2 | -5,39 | -3,54 | -4,24 | -4,45 | -6,54 | 18,98 | 0,00 | |
| EBITDA-Margin3 | -66,38 | -30,44 | -37,59 | -48,48 | -137,68 | 246,74 | 0,00 | |
| EBIT1,4 | -5,82 | -4,14 | -4,91 | -5,13 | -7,60 | 18,67 | 0,00 | |
| EBIT-Margin5 | -71,68 | -35,60 | -43,53 | -55,88 | -160,00 | 242,70 | 0,00 | |
| Net Profit (Loss)1 | -6,01 | -5,89 | -6,40 | -6,80 | -15,42 | 18,02 | 0,00 | |
| Net-Margin6 | -74,02 | -50,65 | -56,74 | -74,07 | -324,63 | 234,27 | 0,00 | |
| Cashflow1,7 | -6,89 | -4,87 | -5,20 | -4,53 | -2,40 | -1,10 | 0,00 | |
| Earnings per share8 | -4,10 | -4,00 | -4,30 | -4,50 | -8,67 | 9,01 | -1,80 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: BDO
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Marinomed Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2N9MM | ATMARINOMED6 | AG | 10,70 Mio € | 01.02.2019 | Halten | 8FWR88QM+8R |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -8,92 | 2,01 | -4,44 | -1,18 | -1,52 | -9,72 | 1,39 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 11.06.2026 | 16.07.2026 | 22.04.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -41,34% | -63,78% | -70,99% | -75,12% | -93,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
